Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCX6239
- Development stage
- Preclinical
- Lead developer
- ChemoCentryx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CCX6239 is a novel, potent, orally available small molecule inhibitor of C-C chemokine receptor type 4 (**CCR4**), developed for its potential utility in the treatment of allergic airways disease and cancer. By antagonizing CCR4, CCX6239 is designed to interfere with chemokine-driven recruitment of immune cells, potentially reducing inflammation in conditions like asthma and enhancing anti-tumor immunity. Preclinical studies have demonstrated that CCX6239 can enhance the effectiveness of immune checkpoint inhibitors in cancer models, suggesting possible applications in oncology for combinatorial therapies. The developer is ChemoCentryx.
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)
Beyond the preview
Go deeper on CCX6239.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCX6239.